Overview
flowchart TD
companies_neurocrine_bioscienc["Neurocrine Biosciences"]
companies_neurocrine_bioscienc["NASDAQ"]
companies_neurocrine_bioscienc -->|"related to"| companies_neurocrine_bioscienc
style companies_neurocrine_bioscienc fill:#81c784,stroke:#333,color:#000
companies_neurocrine_bioscienc["NBIX"]
companies_neurocrine_bioscienc -->|"related to"| companies_neurocrine_bioscienc
style companies_neurocrine_bioscienc fill:#81c784,stroke:#333,color:#000
companies_neurocrine_bioscienc["biotechnology"]
companies_neurocrine_bioscienc -->|"related to"| companies_neurocrine_bioscienc
style companies_neurocrine_bioscienc fill:#81c784,stroke:#333,color:#000
companies_neurocrine_bioscienc["company"]
companies_neurocrine_bioscienc -->|"related to"| companies_neurocrine_bioscienc
style companies_neurocrine_bioscienc fill:#81c784,stroke:#333,color:#000
style companies_neurocrine_bioscienc fill:#4fc3f7,stroke:#333,color:#000
Neurocrine Biosciences,NASDAQ: NBIX) is a biotechnology company headquartered in San Diego, California, focused on developing treatments for neurological and psychiatric disorders. The company has established itself as a leader in addressing unmet needs in movement disorders, particularly Parkinson's disease and Huntington's disease["@neurocrine"]. Founded in 1992, Neurocrine has successfully brought multiple CNS drugs to market, including Ingrezza (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and Orthodopa (opicapide) for Parkinson's disease OFF periods.
...Overview
Mermaid diagram (expand to render)
Neurocrine Biosciences,NASDAQ: NBIX) is a biotechnology company headquartered in San Diego, California, focused on developing treatments for neurological and psychiatric disorders. The company has established itself as a leader in addressing unmet needs in movement disorders, particularly Parkinson's disease and Huntington's disease["@neurocrine"]. Founded in 1992, Neurocrine has successfully brought multiple CNS drugs to market, including Ingrezza (valbenazine) for tardive dyskinesia and Huntington's disease chorea, and Orthodopa (opicapide) for Parkinson's disease OFF periods.
Beyond its commercial portfolio, Neurocrine has entered the gene therapy space through a partnership with [Roche](/companies/roche) on an AAV gene therapy program for [Dravet syndrome](/diseases/dravet-syndrome) targeting the [SCN1A](/entities/scn1a) gene["@roche2025"].
Pipeline Overview (March 2026)
| Program | Target/Mechanism | Indication | Phase | Status |
|---------|-----------------|------------|-------|--------|
| Ingrezza (valbenazine) | VMAT2 inhibitor | Tardive Dyskinesia | Approved | Commercial |
| Ingrezza (valbenazine) | VMAT2 inhibitor | Huntington's Disease chorea | Approved | Commercial |
| Orthodopa (opicapide) | COMT inhibitor | Parkinson's OFF periods | Approved | Commercial |
| CRENE (NB-188) | VMAT2 inhibitor (alternate formulation) | Tardive dyskinesia | Phase 1 | Active |
| NBI-1065846 | KCNQ2/3 channel opener | Focal onset seizures | Phase 1 | Active (Roche partnership) |
| SCN1A AAV (NB-XXXXX) | Gene replacement | Dravet syndrome | Preclinical | IND-enabling (Roche partnership) |
| NBI-817 | AADC gene therapy | Parkinson's Disease | Preclinical | Research |
| NBI-921 | Norepinephrine modulator | Parkinson's Disease | Discovery | Research |
Approved Products
Ingrezza (valbenazine)
Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor approved for the treatment of tardive dyskinesia (2017) and chorea in Huntington's disease (2023)[@ingrezza]. It is one of the fastest-growing CNS drugs in the United States.
- Indication: Tardive dyskinesia, Huntington's disease chorea
- Mechanism: VMAT2 inhibition reduces presynaptic dopamine packaging, alleviating involuntary movements
- Dosing: Once-daily oral administration
- Market: One of the leading treatments for tardive dyskinesia with strong commercial performance
Orthodopa (opicapide)
Orthodopa is a COMT inhibitor approved for Parkinson's disease OFF periods (2023), delivered as a continuous subcutaneous infusion[@nbix2025].
- Indication: Motor fluctuations (OFF periods) in Parkinson's disease
- Mechanism: COMT inhibition prolongs levodopa half-life, providing more continuous dopaminergic stimulation
- Delivery: Continuous subcutaneous infusion (novel delivery approach)
- Market: Addresses significant unmet need for reducing OFF time
Roche Partnership: SCN1A AAV Gene Therapy for Dravet Syndrome
Background
Neurocrine entered a collaboration with Roche in the neuroscience gene therapy space, focusing on rare genetic epilepsies with high unmet need. The partnership targets [Dravet syndrome](/diseases/dravet-syndrome) — caused by loss-of-function variants in the [SCN1A](/entities/scn1a) gene — using an AAV-delivered gene therapy approach[@roche2025].
SCN1A Program Details
The SCN1A gene therapy program represents Neurocrine's entry into the genetic medicine space:
- Target: [SCN1A](/entities/scn1a) (sodium channel neuronal type 1 alpha subunit, Nav1.1)
- Indication: [Dravet syndrome](/diseases/dravet-syndrome)
- Approach: AAV-delivered full-length SCN1A gene replacement
- Technical challenge: SCN1A coding sequence (~6 kb) approaches the AAV packaging limit (~4.7 kb)
- Delivery strategy: Likely intracerebroventricular (ICV) or intrathecal administration to maximize CNS exposure
- Stage: IND-enabling studies (as of March 2026)
Competitive Context
The program competes in the Dravet gene therapy landscape alongside:
| Company | Approach | Stage |
|---------|----------|-------|
| [Stoke Therapeutics](/companies/stoke-therapeutics) | ASO (STK-001) | Phase 2 (FDA BTD) |
| [Encoded Therapeutics](/companies/encoded-therapeutics) | AAV CRISPRa (ETX101) | Phase 1 |
| Roche/Neurocrine | AAV gene replacement | IND-enabling |
The AAV gene replacement approach differs from both the ASO (repeat dosing, non-viral) and CRISPRa (transcriptional activation) strategies. Like ETX101, an AAV approach would provide potentially durable, single-dose treatment — but with expression of the full SCN1A gene rather than CRISPR-mediated upregulation.
Key Challenges
Gene size: SCN1A (~6 kb coding) requires careful construct design — potentially mini-gene approaches or dual-vector strategies
Cell-type targeting: Expression must be enriched in GABAergic interneurons (where Nav1.1 loss causes Dravet) to avoid worsening seizures via excitatory neuron expression
Timing: Early intervention before developmental damage is critical
Regulatory path: Novel approach with no precedent for AAV gene therapy in Dravet specifically
Immunogenicity: Pre-existing AAV antibodies may limit dosing in some patientsResearch Programs
NBI-817 (AADC Gene Therapy)
NBI-817 is an AAV-based gene therapy approach for Parkinson's disease designed to restore dopamine synthesis through delivery of the aromatic L-amino acid decarboxylase (AADC) gene directly to the striatum[@aadc2021].
- Mechanism: AAV vector delivers AADC gene to striatal neurons, enabling neurons to convert levodopa to dopamine
- Rationale: Addresses the fundamental dopamine deficit in PD with potential for long-lasting benefit
- Partnership: Voyager Therapeutics collaboration
- Status: Preclinical, IND-enabling
NBI-921
NBI-921 is a novel norepinephrine modulator in discovery research for Parkinson's disease, targeting the noradrenergic system which plays important roles in motor control and non-motor symptoms including cognitive dysfunction, depression, and autonomic symptoms[@norepinephrine2020].
- Target: Norepinephrine receptors and transporters
- Status: Discovery stage, lead optimization
KCNQ2/3 Channel Opener (NBI-1065846)
A program targeting KCNQ2/KCNQ3 potassium channels (the M-current) for focal onset seizures, in partnership with Roche. This is distinct from the SCN1A Dravet program and leverages Neurocrine's expertise in ion channel modulation for epilepsy.
- Mechanism: Enhances M-current (Kv7.2/Kv7.3 channels), stabilizing neuronal membrane potential
- Indication: Focal onset seizures
- Stage: Phase 1
Partnerships
| Partner | Focus Area | Programs |
|---------|------------|----------|
| [Roche](/companies/roche) | Gene therapy | SCN1A AAV (Dravet), KCNQ2/3 opener |
| Voyager Therapeutics | Gene therapy | VY-AADC, NBI-817 (AADC for PD) |
| Teva Pharmaceutical | CNS development | Various |
Financial Overview (March 2026)
| Metric | Value |
|--------|-------|
| Exchange | NASDAQ |
| Ticker | NBIX |
| Market Cap | ~$8-12B |
| Revenue (2025) | ~$1.5-1.8B (Ingrezza + Orthodopa) |
| Employees | ~1,200-1,500 |
| Cash Position | ~$1.2B |
| R&D Budget | ~$500M annually |
Competitive Position
| Strengths | Challenges |
|-----------|-----------|
| Profitable commercial products (Ingrezza, Orthodopa) | Limited gene therapy experience |
| Established CNS commercial infrastructure | SCN1A program is early-stage |
| Roche partnership provides resources and expertise | Faces established competitors (Stoke, Encoded) |
| Strong cash position and profitability | AAV manufacturing is capital-intensive |
| Ion channel expertise (KCNQ2/3 opener) | Dravet market is small and competitive |
Hub Page Cross-Links
- [AAV Gene Therapy for Neurodevelopmental Epilepsy — Hub](/therapeutics/aav-gene-therapy-neurodevelopmental-epilepsy)](/therapeutics)
- [Dravet Syndrome](/diseases/dravet-syndrome)](/diseases/dravet-syndrome)
- [SCN1A Gene](/entities/scn1a)](/entities)
- [Roche](/companies/roche)](/companies/roche)
- [Stoke Therapeutics](/companies/stoke-therapeutics)](/therapeutics)
- [Encoded Therapeutics](/companies/encoded-therapeutics)](/therapeutics)
- [Ingrezza](/therapeutics/ingrezza)](/therapeutics)
- [Orthodopa](/therapeutics/orthodopa)
External Links
- [Neurocrine Biosciences](https://www.neurocrine.com)
- [Investor Relations](https://investor.neurocrine.com)
- [Pipeline](https://www.neurocrine.com/pipeline)
References
[Neurocrine Biosciences Corporate Website](https://www.neurocrine.com)
[Company Pipeline - Neurocrine Investor Presentation 2024](https://investor.neurocrine.com)
[AADC Gene Therapy for Parkinson's Disease, Molecular Therapy (2021)](https://pubmed.ncbi.nlm.nih.gov/32895569/)
[Norepinephrine in Parkinson's Disease, Nature Reviews Neurology (2020)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Ingrezza FDA Approval](https://www.fda.gov/drugs)
[Neurocrine Biosciences Corporate Presentation Q1 2025](https://www.neurocrine.com/investors)
[Roche Neuroscience Pipeline - SCN1A Program](https://www.roche.com/research/pipeline)